Security Snapshot

CYMABAY THERAPEUTICS INC - COM (CBAY) Institutional Ownership

CUSIP: 23257D103

13F Institutional Holders and Ownership History from Q3 2014 to Q2 2024

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COM
Symbol
CBAY
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CBAY - CYMABAY THERAPEUTICS INC - COM is tracked under CUSIP 23257D103.
  • 13F reference-period holder data is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder data for the Q2 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

23257D103

13F reference period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

CBAY full holder history

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
40
Headline period
n/a
Rows shown
1-25 of 40
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2024 Q2 0 $0 -$1,303,383 0
2024 Q1 650 $21,077 -$2,704,600,701 $32.43 1
2023 Q4 114,757,534 $2,710,586,445 +$124,665,303 $23.62 198
2023 Q3 108,273,662 $1,614,512,313 +$248,853,575 $14.91 186
2023 Q2 92,788,933 $1,016,090,071 +$58,880,451 $10.95 148
2023 Q1 88,862,154 $774,919,455 +$217,014,250 $8.72 138
2022 Q4 63,439,729 $397,760,786 +$20,831,383 $6.27 115
2022 Q3 62,267,312 $217,873,004 -$2,093,777 $3.50 93
2022 Q2 63,013,354 $185,887,462 -$5,592,533 $2.95 96
2022 Q1 65,210,419 $202,829,241 +$4,287,026 $3.11 106
2021 Q4 63,819,650 $215,650,821 +$33,681,613 $3.38 107
2021 Q3 46,366,590 $169,293,393 -$24,483,402 $3.65 107
2021 Q2 52,158,607 $227,403,375 -$14,358,449 $4.36 108
2021 Q1 55,432,387 $251,650,727 -$7,053,547 $4.54 126
2020 Q4 56,362,930 $323,576,998 -$33,068,798 $5.74 140
2020 Q3 59,077,972 $428,045,235 +$20,308,782 $7.24 114
2020 Q2 59,822,943 $208,780,865 +$27,504,263 $3.49 108
2020 Q1 52,340,863 $77,465,816 -$4,311,446 $1.48 95
2019 Q4 58,132,775 $113,943,284 -$77,201,493 $1.96 108
2019 Q3 64,099,042 $328,177,512 -$24,948,443 $5.12 129
2019 Q2 67,803,698 $485,410,405 -$48,862,937 $7.16 130
2019 Q1 68,333,029 $907,454,217 +$143,542,378 $13.28 139
2018 Q4 58,228,856 $458,218,605 +$9,215,236 $7.87 125
2018 Q3 56,113,417 $621,728,888 -$4,917,454 $11.08 129
2018 Q2 56,251,498 $754,888,970 +$105,637,327 $13.42 113
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .